Patent · US Active

Combination therapy with CD4 lymphocyte depletion and MTOR inhibitors

US10039825B2 · kind B2 · utility

1Cited by
2References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 25, 2016
Grant dateAug 7, 2018
Priority date—
Expiry dateJul 25, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.